(AOF) – Adocia announces a net loss of 9.39 million euros for the first half of 2023, compared to a positive net result of 4.25 million a year ago. The biotech specializing in metabolic diseases, mainly diabetes and obesity, displays a cash position of 16 million euros as of August 31 compared to 17.4 million as of December 31, 2022. The turnover of 1.6 million The euros “comes mainly from licensing and collaboration agreements signed with the company Tonghua Dongbao (THDB)”.
“This first half of the year was marked by a difficult period during which we had to suspend the trading of the course,” declares the new CEO Olivier Soula, appointed on May 15, 2023. “I am delighted that ultimately, we came out of it more strong as a company and that we have succeeded in clearing our debt, strengthening our financial position and, above all, taking an important step towards a partnership with Sanofi on M1Pram”. “Our priority now is to finalize a global licensing agreement for M1Pram,” he concludes.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
